Capital World Investors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Capital World Investors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-205,400	Closed	-$22M	–	538
2023 Q1	$22M	Buy	205,400 +75,000	+58%	+$8.63M	﹤0.01%	436
2022 Q4	$14.3M	Buy	+130,400	New	+$8.46M	﹤0.01%	473

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Capital World Investors's RXDX Position: Q2 2023 in Review

Capital World Investors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 205,400 shares — an estimated $22M sold.

Capital World Investors first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $22M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Capital World Investors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Capital World Investors sold 205,400 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $22M.
Capital World Investors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Capital World Investors's Prometheus Biosciences, Inc. Common Stock position peaked at $22M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Capital World Investors's 13F filing for Q2 2023, filed 11 Aug 2023.